TacticScaleWhat Imeik Technology Development (爱美客) Does & How It Makes Money (300896.SZ)
Updated October 2026 · reflects Imeik Technology Development's latest reported financials
Chinese maker of injectable aesthetic medicine products and dermal fillers. It earns revenue by selling its injectable gels, fillers, implant threads and skin care products to medical aesthetic institutions, which use them on consumers in cosmetic procedures.
How Imeik Technology Development makes money
It earns revenue by selling its injectable gels, fillers, implant threads and skin care products to medical aesthetic institutions, which use them on consumers in cosmetic procedures.
What Imeik Technology Development does
Imeik Technology is a Beijing-based company focused on researching, developing and commercializing biomedical materials and biopharmaceutical products, with its core business in aesthetic medicine. Its portfolio centers on sodium hyaluronate (hyaluronic acid) based injectables, including cross-linked gels with PLLA-b-PEG microspheres, modified and composite hyaluronate injections, and hyaluronate-HPMC gels, plus a PVA gel ball composite gel. Beyond injectables, the company offers poly facial implant threads for lifting and a line of skin care products. It sells to medical aesthetic institutions in China, which makes it a supplier to the country's cosmetic procedure market. The company was founded in 2004.
Products & services
- Cross-linked sodium hyaluronate gel with PLLA-b-PEG microspheres
- Poly facial implant thread
- Sodium hyaluronate composite solution for injection
- Modified sodium hyaluronate gel for injection
- Medical sodium hyaluronate-HPMC gel
- Skin care products
爱美客是做什么的？
爱美客是一家总部位于北京的公司，主要从事生物医用材料和生物医药产品的研发与转化，核心业务是医疗美容。产品以透明质酸钠（玻尿酸）注射类产品为主，包括含PLLA-b-PEG微球的交联透明质酸钠凝胶、修饰透明质酸钠凝胶、透明质酸钠复合溶液，以及透明质酸钠-羟丙基甲基纤维素凝胶等。 此外，公司还提供聚对二氧环己酮面部埋植线和护肤品，主要面向国内医疗美容机构销售。公司成立于2004年。
What is Imeik Technology Development worth?
On an owner-earnings DCF, Imeik Technology Development's most-likely value is about ¥67 versus a recent price near ¥94 (40% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~¥32) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
InMode (INMD) · MeHow Innovative (301363.SZ) · ICU Medical (ICUI) · Hybio Pharmaceutical (300199.SZ)